Company profile: Enobia Pharma
1.1 - Company Overview
Company description
- Provider of therapies for serious genetic bone disorders, focused on conditions with no approved treatments.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Enobia Pharma
Clarus Therapeutics
HQ: United States
Website
- Description: Provider of androgen-based biopharmaceutical therapies, developing medicines for men and women, including JATENZO, an oral testosterone replacement therapy for men with conditions associated with a deficiency or absence of endogenous testosterone.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clarus Therapeutics company profile →
Madrigal Pharmaceuticals
HQ: United States
Website
- Description: Provider of THR-β-selective agonist therapy for NASH, a once-daily, oral, liver-directed treatment granted accelerated approval by the U.S. FDA. Offers multiple Phase 3 clinical trials in NASH, including in patients with compensated cirrhosis; conducts NASH/MASH R&D focused on the THR-β pathway; and supports educational programs for healthcare professionals on NASH.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Madrigal Pharmaceuticals company profile →
Neurocrine Biosciences
HQ: United States
Website
- Description: Provider of therapies for neurological and endocrine-related diseases, including FDA-approved Ingrezza (valbenazine) for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa and Oriahnn (commercialized by AbbVie) for endometriosis pain and heavy menstrual bleeding associated with uterine fibroids; and investigational Crinecerfont for congenital adrenal hyperplasia due to 21-hydroxylase deficiency, NBI-1065890 (VMAT2 inhibitor), and NBI-1065845 (AMPA potentiator).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neurocrine Biosciences company profile →
ViaCyte
HQ: United States
Website
- Description: Provider of preclinical regenerative medicine therapies for diabetes, based on differentiation of stem cells into pancreatic beta-cell precursors implanted subcutaneously in an encapsulation device.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ViaCyte company profile →
Altimmune
HQ: United States
Website
- Description: Provider of vaccines and other biological products to address unmet market and public health needs, using proprietary non-invasive intranasal delivery to stimulate robust and durable immune responses for prevention; programs include pemvidutide, a GLP-1/glucagon dual receptor agonist being developed for obesity and for metabolic dysfunction-associated steatohepatitis (MASH). Proof of principle shown in animals and initial human clinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Altimmune company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Enobia Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Enobia Pharma
2.2 - Growth funds investing in similar companies to Enobia Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Enobia Pharma
4.2 - Public trading comparable groups for Enobia Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →